Compound 23 Chemical Structure oral interleukin 17A modulator - LEO Pharma Research & Early Development, Ballerup, DK

oral interleukin 17A modulator

favorable in vivo PK profile in multiple species

from a previous patent and SBDD

J. Med. Chem.

LEO Pharma Research & Early Development, Ballerup, DK

Context. “Compound 23” (LEO Pharma) is an oral IL-17A protein−protein interaction modulator being developed for psoriasis and other inflammatory diseases. Like most cytokines, the involvement of IL-17A in chronic…


 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.